Home » Newsletters » BioWorld Science

BioWorld Science

March 13, 2019

View Archived Issues

Sig1R identified as upstream modulator of canonical autophagy

Stemline licenses worldwide rights to novel RET kinase inhibitor

Discovery and characterization of a novel CCK-1R agonist, NN-9056

CARD9 pathway as a potential therapeutic target in allergic airway disease

First subject dosed in phase IIb/III study of TD-1473 in patients with ulcerative colitis

Lipocine presents topline results from 16-week liver fat imaging study of LPCN-1144

Not just for cancer anymore, CAR T cells tested in lupus

Discovery of selective and potent arylpiperazine-based DHFR inhibitors for toxoplasmosis treatment

Novartis initiates phase II study of MIJ-821 in patients with treatment-resistant depression

Design of tricyclic indazoles as selective ER degrader antagonists for ERalpha+ breast tumors

Servier and Oncodesign enter LRRK2 inhibitor R&D collaboration

PANK4 gene mutation tied to congenital posterior cataract

FDA approves Rocklatan to reduce IOP in open-angle glaucoma or ocular hypertension

Positive interim results reported from phase II study of NBI-74788

Bristol-Myers Squibb discovers new Toll-like receptor 7 agonists

Researchers describe TFEB as a potential therapeutic target for AMD

AbbVie discloses Mcl-1 inhibitors

Friedrich-Alexander-Universitaet Erlangen-Nuernberg and collaborators patent MOR agonists

The University of Texas, Chempartner present ATR kinase inhibitors

New aryl hydrocarbon receptor antagonists identified at Kyn Therapeutics

Design of novel transgenic pancreatic adenocarcinoma mouse model

New mouse model of multiple sclerosis points to NLRX1 as a treatment target

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 19, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...